Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Cancer

Granulocyte macrophage colony-stimulating factor (GM-CSF; CSF2); IL-4 (BSF1)

Mouse studies suggest a GM-CSF and IL-4 fusion molecule called GIFT4 could be useful for treating various cancers. In a mouse model of melanoma, i.v. treatment with GIFT4 increased expansion of endogenous B cells and decreased tumor growth compared with vehicle treatment or separate administration of
GM-CSF and IL-4. In human cell cocultures, T cells from patients with melanoma primed with GIFT4 showed greater killing of melanoma cells than T cells primed with separate administration of GM-CSF and IL-4. Next steps include developing GIFT4-augmented autologous B cells as a transfusion product that could be combined with existing cancer therapy regimens and developing GIFT4 as an injectable therapeutic protein.

SciBX 7(29); doi:10.1038/scibx.2014.860
Published online July 31, 2014

Patent application filed; available for licensing from Emory University
Contact: Clifford Michaels, Emory University, Atlanta, Ga.
e-mail:
ccmicha@emory.edu

Deng, J. et al. Cancer Res.; published online June 17, 2014;
doi:10.1158/0008-5472.CAN-14-0708
Contact: Jacques Galipeau, Emory University, Atlanta, Ga.
e-mail:
jgalipe@emory.edu